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Abstract 
 
Stem cell markers are powerful prognostic tools to predict cancer 
progression and cancer-specific survival in patients with metastatic prostate 
cancer (PC). Among these is the SRY (sex determining region y)-box 2 
(SOX2) gene. SOX2 is expressed in metastatic lesions of androgen 
resistant human PC. In primary PC, SOX2 was overexpressed and found to 
be as useful as Gleason and prostate specific antigen (PSA) for prognosis 
in a small series of 30 patients. Experimental models in mice suggest that 
SOX2-expressing basal cells in p63 and Pten-null mice contribute to the 
luminal population and tumorigenesis. SOX2 is an androgen receptor (AR) 
repressed gene found to promote castration resistant PC (CRPC) 
phenotypes. Moreover, it is involved in paclitaxel resistance of the PC cell 
line PC-3 via the PI3K/Akt pathway. Despite its apparently crucial role in 
metastasis, the actual role of SOX2 and whether or not it might be 
modulated in bone metastatic lesions of PC has not been well documented. 
After obtaining a biopsy positive for PC, patients face the option of waiting 
or performing a radical prostatectomy (RP) or radiotherapy. RP is a high 
morbidity associated surgery involving also large economical burden to the 
healthcare system. Indeed, the available therapies regarding the 
management of PC significantly interfere with the patient wellbeing and thus 
the development of novel diagnostic and therapeutic tools is mandatory. As 
such, this project aims at developing SOX2-based diagnostic criteria and to 
assess its possible role in PC progression. More precisely, the main 
purpose of this study, using a series of PC cases and cell lines is to study 
SOX2 and accurately assess its role in invasion. Here, we successfully 
validated SOX2 as a pivotal player in the early progression and invasion of 
prostate carcinomas. We have demonstrated that SOX2 silencing mediated 
by siRNAs stemmed a significant decrease in the migration capacities and 
an increase in the apoptotic process of SOX2 knocked-down PC3 cells. 
These results further support the hypothesis that SOX2 might take part of 
an important transcription program certainty  
 
 
  
 
 responsible for modulating the establishment of metastasis. We also found 
that SOX2 was overexpressed in basal-like cells of human PC tissue, and 
not in normal adjacent tissue, further supporting the possibly involvement of 
SOX2 in the tumorigenesis of the prostate. In addition, we also evaluated 
the relationship of the expression of SOX2 with a series of clinical and 
histopathological criteria and found that it was significantly associated with 
an increased risk of relapsing after primary therapy, pointing to its possible 
role in tumour recurrence. In conclusion, we believe that the 
characterization of the SOX2 activities throughout the development, 
progression, and relapse of prostate carcinomas will become a major step 
forward towards understanding the biology underpinning this disorder. 
Ultimately, such understandings can hopefully lead to the discovery of a 
SOX2 repressor which could potentially be used for anti-cancer therapy. 
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Resumo 
 
 
Os marcadores de células estaminais constituem excelentes 
ferramentas de prognóstico para determinar a progressão e 
sobrevivência de pacientes diagnosticados com cancro da próstata 
metastático. Dentro deste grupo de marcadores encontra-se o 
SOX2, um fator de transcrição expresso em lesões metastáticas de 
carcinomas da próstata resistentes aos androgénios. Em 
neoplasmas primários da próstata, a expressão de SOX2 encontra-
se frequentemente elevada, apresentando uma utilidade semelhante 
ao fator Gleason, e ao antigénio específico da próstata para o 
prognóstico numa pequena serie de 30 pacientes. Modelos 
experimentais em ratinhos apontam que células basais SOX2+ 
contribuem para a população de células luminais e para a 
tumorigénese em ratinhos mutantes para a p63 e o PTEN. O SOX2 
é um gene cuja expressão é reprimida pelo receptor de androgénios, 
possuindo um papel essencial na aquisição de fenótipos de 
resistência à castração. Além disso, encontra-se igualmente 
envolvido nos processos de aquisição de resistência ao paclitaxel na 
linha celular PC3 através da via de sinalização PI3K/Akt. No entanto, 
apesar do seu papel no aparecimento de metástases ser cada vez 
mais evidente, a sua função e a forma como é modulado neste tipo 
de lesão permanece ainda por identificar. Após confirmação de um 
diagnóstico positivo para cancro da próstata, ao paciente podem ser 
apresentadas várias vias de tratamento, incluindo opções de 
monotorização ativa, prostectomia radical ou radioterapia. 
Atualmente, a prostectomia radical constitui uma cirurgia associada 
a elevadas taxas de mortalidade e a elevados gastos económicos 
para o sistema de saúde. Além disso, as terapias habitualmente 
direcionadas para o cancro da próstata interferem significativamente 
com a qualidade de vida do paciente. Assume-se assim, que o 
desenvolvimento de novas ferramentas terapêuticas, assim como de  
  
 
 diagnóstico, será de extrema urgência. Este projeto tem como 
objetivo avaliar a possível aplicação do SOX2 no desenvolvimento 
de novos critérios de diagnóstico, assim como determinar o seu 
possível envolvimento na progressão de carcinomas da próstata. 
Especificamente, o principal objetivo deste estudo é compreender 
qual o papel exato do SOX2 nos processos invasivos, utilizando uma 
série de casos e linhas celulares de cancro da próstata. Assim, foi 
possível demonstrar que o silenciamento do SOX2 mediado por 
siRNAs fomentou uma redução significativa das capacidades 
migratórias, e ainda, um aumento da morte celular programada nas 
células da linha PC3, onde a expressão de SOX2 foi silenciada. 
Verificamos que a expressão de SOX2 em células basais de 
amostras de cancro da próstata, encontrava-se aumentada em 
comparação ao tecido adjacente normal, corroborando a hipótese de 
que o SOX2 poderá estar envolvido na tumorigénese da próstata. 
Procedeu-se ainda a uma avaliação da relação existente entre a 
expressão de SOX2 e uma série de critérios clínicos e 
histopatológicos. Verificou-se que o SOX2 encontra-se 
significativamente associado a um maior risco de recorrência após 
tratamento primário, sugerindo que este fator de transcrição poderá 
desempenhar uma função importante nos mecanismos subjacentes 
à recorrência tumoral. De um modo geral, a caraterização das 
atividades do SOX2 ao longo do desenvolvimento, progressão e 
recorrência de carcinomas da próstata, tornar-se-á um importante 
passo no sentido de compreender os processos biológicos implícitos 
nesta condição. Em última análise, tal poderá conduzir à descoberta 
de novas estratégias promissoras para o tratamento de carcinomas 
da próstata, baseadas na repressão de SOX2. 
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INTRODUCTION 
 
1. Anatomy and histology of the human prostate. 
The prostate is a walnut-sized fibromuscular gland of the male reproductive 
system sitting in the pelvis, directly below the bladder and surrounding the 
urethra. It as a pivotal role in producing a part of the seminal fluid and thus it is 
indirectly implicated in motility and nourishment of the sperm (McNeal, 1972; 
Marandola et al., 2004). 
The anatomy of the prostate was surrounded by controversy for several years. 
Indeed, early descriptions of the human prostate envisage that, comparable to 
other mammals, the gland followed a lobar pattern of development (Lowsley, 
1912). Nonetheless, after birth it is possible to denote that foetal lobes coalesce 
and give rise to a homogeneous structure. Thus, McNeal (1981) proposed the 
existence of several zones categorized into the peripheral (70 percent of 
glandular tissue), central (20 percent of the glandular tissue), and transitional 
zones (5 percent of glandular tissue), and also the anterior fibromuscular 
stroma (AFMS) (figure 1) (McNeal et al., 1980; McNeal, 1981; McNeal, 1981a). 
The peripheral zone is the main location for the development of a subset of 
prostate associated lesions, including prostatitis and carcinomas, and extends 
around the posterolateral peripheral area of the gland from the apex to the base 
(Lee et al., 2011). On the other hand, the central zone is a cone-shaped region 
wherein less than 10 percent of carcinomas develop. This region embraces the 
majority of the prostate base and surrounds the ejaculatory ducts, which empty 
bilaterally into the urethra in a precise point, the verumontanum (Bhavsar and 
Verma, 2014). Lastly, the transition zone is composed by two small symmetrical 
lobules sideways to the urethra in the midland (Lee et al., 2011). The vast 
majority of benign prostatic hyperplasia (BPH) and up to 20 percent of prostate 
cancer (PC) develops in this region. Nevertheless, and despite some 
uncertainty, transitional carcinomas have been positioned as lower malignant 
potential when compared to the peripheral ones (Greene et al., 1991; Reissigl 
et al., 1997).  
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Figure 1 | Sagittal view of the human adult prostate gland elucidating the zonal division 
of the gland as described by McNeal in 1981. The prostate can be divided into several zones, 
i.e., peripheral, transition and central zones, which are surrounded by the AFMS (Cohen et al., 
2008). 
 
The epithelium of the prostate is organized as glandular acini consisting of 
basal, luminal, transient, and neuroendocrine cell groups (figure 2) (Isaacs and 
Coffey, 1989; Long et al., 2005). The luminal secretory cell layer is composed of 
tall columnar highly-differentiated androgen-dependent cells (Masai et al., 1990) 
frequently characterized by the expression of low molecular-mass cytokeratin’s 
(CKs) (mostly CK8 and CK18) and the cell-surface marker CD57 (Sherwood et 
al.,1990; Sherwood et al., 1991; Okada et al., 1992; Liu et al., 1997). Luminal 
cells have a master role in the synthesis and secretion of several components 
of the seminal fluid, including PSA (prostate specific antigen), PAP (prostatic 
acid phosphatase) and human kallikrein-2 (Long et al., 2005). Contrarily, the 
basal compartment consists of undifferentiated androgen-independent cuboidal 
epithelial cells commonly characterized by the expression of high-molecular-
mass CK5 and 14 and the cell-surface marker CD44 (Liu et al., 1997; Yang et 
al., 1997; van Leenders et al., 2000). Importantly, the presence of stemness 
subpopulations within this layer provides the basis for all the prostatic epithelial 
cells. Indeed, mitosis yields groups of intermediate cells (Wernert et al., 1987; 
Fry et al., 2000; Hudson et al., 2001) which ultimately differentiate into luminal 
cells as they migrate towards the luminal compartment (Isaacs and Coffey, 
1989; Long et al., 2005). In addition, the prostate contains a less abundant 
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group of androgen-independent and non-proliferating terminally differentiated 
NE cells intermingled within the luminal and basal cell layers (Noordzij et al., 
1995; Abrahamsson, 1996). The majority of NE cells are identified based on 
morphology and secretory products, i.e., serotonin (Abrahamsson et al., 1987; 
Abdul et al., 1994), synaptophysin (di Sant’Agnese, 1998) and chromogranin A 
(Huttner et al., 1991) and have an apparent enrolment in growth, differentiation 
and carcinogenic processes (di Sant’Agnese, 1998; Sciarra et al., 2003).  
The prostate gland is further supported by the existence of the AFMS wherein 
smooth muscle cells, fibroblasts, various immune cells, autonomic nerve fibers, 
components of the extracellular matrix (ECM) and endothelial cells are 
positioned (figure 2) (Barron and Rowley, 2012).  
 
 
 
Figure 2 | Cellular components of the human prostate gland. Secretory epithelial cells are 
positioned on the basement membrane and secrete products into the acinar lumen. Basal cells 
and NE cells are also present in the prostate gland, which is further supported by a stromal 
compartment. The later is composed of smooth muscle, fibroblasts, blood vessels, autonomic 
nerve fibers, inflammatory cells, and ECM components (Barron and Rowley, 2012). 
 
The role of stromal-epithelial interactions as well as the outcome engaged are 
not completely understood. However, a growing body of evidence advices that 
the stroma is capable of producing a myriad of growth factors whose function is 
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paramount for the development and growth of both normal and cancerous 
prostate (Ware, 1993; Chung, 1995). 
 
 
2. Cancer: a disease of the genome 
Cancer is a disease of the genome resulting from a successive accumulation of 
genetic and epigenetic modifications which ultimately prompt a cell to survive 
and proliferate in the very harsh microenvironment that defines a tumor. Millions 
of people currently live with a positive diagnosis of cancer. Acquisition of 
invasive and metastatic capacities is an intricate and coordinated series of 
events encompassing the main cause of cancer-related death. Indeed, nearby 
14.1 million new cases were detected in 2012 of which 8.2 million deaths were 
reported (Ferlay et al., 2013). Notwithstanding recent progresses, the disease is 
growing at a frightening pace with 21.4 million cases and 13.2 million deaths 
expected to occur in 2030 possibly due to the continual growth, aging and 
improper lifestyle of the worldwide population (Ferlay et al., 2010).  
PC is often a complex and heterogeneous pathology in many facets of the 
disease, i.e., epidemiological, biological, pathological and clinical criteria. As 
such, research in this field is extremely mandatory. Novel insights into the 
biology underlying its development and proliferation, the causes and, most 
importantly, how it can be prevented and treated are required. All of these 
topics will be discussed above. 
 
 
3. Prostate cancer epidemiology 
In human settings PC is recognized as one of the most common malignancies 
and cancer-related death among men. In fact, nearby 1.1 million cases were 
detected in 2012 and accounted for approximately 15 percent of the global 
cancer burden (Ferlay et al., 2015).  
Based on geographic location, the global commonness of PC diverges 
impressively. These disparity is partly attributed to the routinely implementation 
of PC diagnosis techniques, which are capable of identifying even the clinically 
non-detectable neoplasms. Likewise, since European and North America 
nations possess highest rates of PC testing they exhibit highest rates of PC, 
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whereas countries that register low rates of PC testing, i.e., Asian and African 
nations, exhibit lowermost rates of PC (Marugame and Katanoda, 2006; Kvale 
et al., 2007; Shin et al., 2010). Yet, the Caribbean and African black population 
display higher mortality rates (figure 3) (Ferlay, 2010). Such variances have 
been accredited to the existence of genetic variants (Corder et al., 1995; Platz 
et al., 2000; Shook et al., 2007), the serum levels of sexual hormones (Winters 
et al., 2001) and growth factors (Scher et al., 1995; Tricoli et al., 1999; Winters 
et al., 2001). 
 
 
 
Figure 3 | Worldwide age-standardized PC incidence and mortality rates (Source: 
GLOBOCAN – IARC (2012). Available from http://globocan.iarc.fr). 
 
 
In the Portuguese scenery, PC is the most common malignancy with 6622 
cases being diagnosed in the year of 2012, of which 1582 deaths were reported 
(figure 4) (Ferlay et al., 2012). 
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Figure 4 | Estimated incidence and mortality of cancer for men in Portugal. PC is the most 
frequent type of cancer found in males and the third leading cause of death in 2012, following 
stomach and lung cancer (Source: GLOBOCAN-IARC (2012). Available from 
http://globocan.iarc.fr 
 
Prostate carcinomas are considered to be slow growing neoplasms (Virtanen et 
al., 1999) with incidence and mortality rates tending to escalate with age 
(Franceschi and La Vecchia, 2001). In fact, diagnosing PC in males younger 
than 50 in relatively scarce (Haas and Sakr, 1997). The majority of cases are 
diagnosed in males beyond the age of 50, with the average standing between 
72 and 74 years of age (Grönberg, 2003). The relationship between aging and 
PC is not completely understood. In these respect, literature data highlights that 
aging impacts on the standard expression of numerous genes in the prostate, 
i.e., inflammation, senescence and oxidative stress associated genes, thus 
consenting the inception of the disease (Shen and Abate-Shen, 2010).  
Family history is also a well-known PC risk factor (Goh et al., 2012). The risk of 
developing PC is higher in males whose first-degree relatives possess the 
disease. Indeed, if one or at least two first-degree relatives have PC, the risk of 
developing the disease is two and five to eleven times higher, respectively, in 
comparison to the broad population (Bratt, 2002). Moreover, if the diagnosis is 
performed in a patient with three or more cases running in the family, or at least 
two relatives develop PC at young age, their cancer is defined as truly 
hereditary, i.e., the cancer is caused by inherited high- and low-penetrance 
genes (Grönberg et al., 1994; Schaid, 2004; Heidenreich et al., 2014).  
Regarding racial disparity, African Americans exhibit the highest rates of PC, 
followed by Caucasian, Hispanic, and Asian/Pacific Islander males (American 
Cancer Society, 2003; Crawford, 2003). Indeed, it was previously established 
that African Americans possess a 1.4 and 2 to 3 times higher risk, in 
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comparison to Caucasians, of developing and dying from the disease, 
respectively (American Cancer Society, 2003; Chornokur et al., 2011). 
 
 
4. Etiology  
The heterogeneity perceived in prostate neoplasms advocates that both genetic 
and environmental factors define the likelihood of developing clinical PC 
(Alvarez-Cubero et al., 2012; Heidenreich et al., 2014). Nonetheless, age, 
family history, and ethnicity are currently the only fully-acknowledged PC risk 
factors (Heidenreich et al., 2014). Several genes have been linked to familial 
PC and include HOXB13, RNASEL, EPAC2, MSR1, CHEK2, CAPZB, vitamin D 
receptor, and PON1 (Deutsch et al., 2004; Porkka and Visakorpi et al., 2004; 
Wiklund et al., 2004; Dong, 2006; Ewing et al., 2012). In addition, rare germline 
mutations in BRCA1 and BRCA2 were established to boost the risk of PC 
(Thompson et al., 2001; Leongamornlert et al., 2012). For instance, BRCA2 
mutations have been associated with higher Gleason scores (Mitra et al., 2008), 
poorer prognosis (Castro et al., 2013), and responsible for triggering nearby 5 
percent of young onset PC (Edwards et al., 2004; Kote-Jarai et al., 2011). 
Geographical discrepancies have been attributed to both environmental and 
lifestyle associated factors (Imperato et al., 1996) namely diet, obesity, smoking 
and alcoholic habits, chemical exposure, transmitted infectious disease and 
vasectomy (American Cancer Society, 2014). For instance, it has been reported 
that diets rich in fat, animal proteins, processed meats and dairy foods have the 
potential to enlarge the risk of developing PC (Grönberg, 2003; Nelson et al., 
2003; Deutsch et al., 2004). Contrarily, a number of nutritional elements, i.e., 
selenium, vitamin D and E, have been proposed to hold a protective effect 
against PC (Nelson et al., 2003; Deutsch et al., 2004; Damber, 2008).  
 
 
4.  Pathophysiology  
The advent of solid neoplasms is considered to be a multistep process shaped 
by successive gathering of genetic and epigenetic events. PC is considered to 
be a complex, heterogeneous and multifocal condition with a long natural 
course. In fact, it partakes the capacity of dwell histological for numerous years 
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before progressing to clinical detectable disease (Bostwick, 1989; Sakr et al., 
1994). 
Pathological conditions affecting the prostate of adult males range from benign, 
premalignant to malignant lesions. Most of the benign prostatic hyperplasia 
(BPH) develops nearby the prostatic urethra in the transition zone (De Marzo et 
al., 2007). It is characterized by a non-malignant overgrowth of epithelial and 
stromal cells leading to the enlargement of the prostate, i.e., glandular and 
stromal tissues undergo hyperplasia. This condition is androgen-driven and 
ultimately leads to the onset of lower urinary tract symptoms in aging men 
(Sandhu and Te, 2004; Roehrborn, 2005; Bushman, 2009).  
The notion that the development of PC occurs through a series of early and late 
histological modifications lead to the designation of proliferative inflammatory 
atrophy (PIA), high-grade prostatic intraepithelial neoplasia (HGPIN), and 
atypical small acinar proliferation (ASAP) as the precursor lesions of PC 
(Berney and Warren, 2013). PIA develops in the peripheral zone and is often 
associated with atrophic epithelia, i.e., cells divide at higher rates in regions of 
chronic inflammation (Bostwick and Cheng, 2012). In the case of PIN, it 
regularly develops in the peripheral zone and consists of architecturally pre-
existing benign prostatic acini and ducts delimitated by atypical cells whose 
features resemble those of PC cells (Epstein, 2009; Berney and Warren, 2013). 
Based on cytological features PIN is further stratified into low-grade PIN 
(LGPIN) and HGPIN. In LGPIN the nuclei of cells is enlarged, vary in size, have 
normal or slightly increased chromatin content, and possess small or 
inconspicuous nucleoli (McNeal, 1986). On the other hand, HGPIN is 
characterized by the existence of nuclei enlarged cells, increased chromatin 
content, and prominent nucleoli resembling carcinoma cells. Importantly, only 
HGPIN is associated with disruption of the basal compartment and inverted 
epithelial proliferation, i.e., proliferation occurs in the luminal layer, being for that 
reason, the most likely precursor lesion of PC, probably arising from LGPIN and 
PIA in a time-dependent manner (figure 5) (Putzi and De Marzo, 2000; De 
Marzo et al, 2003; Joniau et al., 2005). 
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Figure 5 | Histopathology of human PC. Hematoxylin-eosin stained sections of prostate 
benign tissue with representative basal (bas) and luminal (lum) cells indicated (A). PIN tissue 
with arrows pointing to regions of hyperplastic epithelium (B). Well-differentiated 
adenocarcinoma (C). Poorly differentiated adenocarcinoma (D). Cellular model of early prostate 
neoplasia progression (adapted from De Marzo et al., 2007; Shen and Abate-Shen, 2010). 
 
ASAP is defined as a focus of small acinar structures rising from atypical 
epithelial cells and includes a variety of lesions i.e., lesions of adenosis, atypical 
adenomatous hyperplasia, intraductal hyperplasia, and acinar atypical 
hyperplasia. These foci can be found in up to 5 percent of PC samples obtained 
by biopsy and are predominantly located at the peripheral zone (Cheville et al., 
1997; Vis et al., 2001). Nevertheless, despite of the fact that the morphologic 
characteristics that the ASAP category exhibits are highly suggestive of cancer 
they are not sufficient to definitely confirm a diagnosis (Bostwick and Meiers, 
2006; Montironi et al., 2006). 
The identification of premalignant change is crucial for preventing the 
emergence of cancer. The majority of malignant histologies are initiated in the 
peripheral zone and are known as adenocarcinomas. Indeed, this 
heterogeneous and multifocal condition comprises 95 percent of the prostate 
malignancy and relies on androgens for progression and survival (Carroll et al., 
2002; Culig and Bartsch, 2006). The clinical course of PC is variable and 
extremely difficult to predict. While some tumors remain organ-confined, others 
might metastasize, even in early stages of the disease, favourably to the bone 
but also to lymph nodes, lungs and liver. When invasion of periprostatic tissue 
occurs, symptoms associated with PC usually manifest. Nevertheless, at this 
point the disease is already incurable, underlining the need of curative early-
stage PC diagnosis prior to the onset of symptoms (DeVita et al., 2008). 
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6. Diagnosis 
In most patients PC was traditionally diagnosed once the disease was already 
incurable. Nevertheless, the number of early-stage cases presently diagnosed 
upon screening or even accidentally up surged. This considerable shift is 
attributed to the emergence of novel screening tools, namely the PSA blood test 
and trans-rectal ultrasound (TRUS)-guided biopsy albeit digital rectal exam 
(DRE) endures as the prime clinical screening tool for PC (Borley and Feneley, 
2009). 
 
6.1. Digital rectal exam.  
The use of DRE as a PC screening tool is grounded on the principle that the 
palpable asymmetry of the gland and, more importantly, hard nodular areas 
comprise clues of cancer. The vast majority of prostate carcinomas develops in 
the peripheral zone and can be screened by DRE when their volume exceeds 
0.2 ml (Heidenreich et al., 2011). Indeed, abnormal DRE is closely associated 
with an enlarged risk of poorer Gleason scores and usually renders the 
performance of biopsy (Okotie et al., 2007; Gosselaar et al., 2008). However, 
the existence of certain DRE-inherent drawbacks ultimately deprive the exam of 
sensitivity, i.e., the bulk of palpable neoplasms are generally advanced in stage 
(Smith and Catalona, 1995) whereas other clinically relevant neoplasms may be 
located in regions unreachable by palpation (Basler and Thompson, 1998).  
 
6.2. Prostate specific antigen blood test. 
PSA is a serine protease produced by the epithelia and ducts of the prostate 
whose function relies on semen liquefication (Wang et al., 1981; Yousef and 
Diamandis, 2001). As such, the presence of higher levels of PSA in the semen 
is conceivable albeit some is capable of evading the gland and enter into 
circulation (Wang et al., 1981). Despite some uncertainty, ample evidence 
highpoints that the upsurge of PSA in the serum might be accredited to the 
disruption of the basal compartment, one of the earliest events of PC (figure 6) 
(Partin et al., 2002; Balk et al., 2003). Indeed, the notion that disease rises the 
serum content of this protein lead to the emergence of the PSA blood test as a 
fundamental screening tool who has revolutionize the management of PC. 
However, the test remains largely deprived of specificity, i.e., the occurrence of 
SOX2 a master gene regulating progression in prostate cancer? 
28 
 
non-cancerous disorders also increases PSA (Andriole et al., 1994), with higher 
serum levels merely expressing a greater probability of effectively possessing 
PC. The traditional threshold for an abnormal PSA test was demarcated at 4.0 
nanograms per millilitre (ng/ml) (Mettlin et al., 1991; Brawer et al., 1992; 
Catalona et al., 1993; Crawford et al., 1996) with the occurrence of cancer and 
even other prostatic disorders being often associated with PSA values 
oscillating between 4 to 10 ng/ml. Indeed, almost 75 percent of tumors are 
spotted within this range and match potentially organ-confined and curable 
neoplasms. Conversely, the amount of localized tumors droplets to less than 50 
percent in patients harbouring total PSA values superior to 10 ng/ml (Catalona 
et al., 1994)  
 
Figure 6 | Presence of PSA in normal (A) and cancerous (B) prostate. In (A) the cells of the 
prostate are tightly arranged with a trivial quantity of PSA leaking into circulation. In the 
presence of PC the basement membrane becomes disrupted and a greater amount of PSA 
leaks into the bloodstream (B) (adapted from http://www.johndonohue.info/psa.html ). 
 
Overall, the European Association of Urology (EAU) guidelines indorse TRUS-
guided systemic biopsy performance in cases whose serum PSA exceeds 4 
ng/ml. Among these, in nearby 20 to 30 percent cases the diagnosis will 
actually be confirmed (Emiliozzi et al., 2001; Wolf et al., 2010). Contrarily, 
patients whose PSA is beneath 4 ng/ml should not be admitted for biopsy. 
However, there is mounting clinical evidence that PSA values lower than 4 
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ng/ml may also be harbouring relevant disease (Catalona et al., 1999; Roehl et 
al., 2002; Heidenreich et al., 2011). Despite this, lowering the PSA threshold 
should not be considered otherwise over-diagnosing and over-treating clinically 
insignificant cancers will become a reality. Instead, aiming to improve the 
accuracy of the test, novel PSA-related approaches were developed and 
involve the assessment  of the PSA density, velocity and doubling time, as well 
as the free/total PSA ratio and the prostate health index (PHI) test (Mottet et al., 
2016). 
 
6.3. Transrectal ultrasound-guided biopsy. 
In PC settings, the utility of TRUS as a first-line screening tool was proven to be 
valueless due to specificity, informative and expense concerns. Actually TRUS 
is rather used as an aid-tool who provides visual guidance for the performance 
of biopsies (Terris, 2002).  
Core needle biopsies comprise the mainstay approach for diagnosing PC. 
Abnormal DRE, elevated or increasing PSA, and earlier identification of 
premalignant change are some of the indications for performing a biopsy 
(Borley and Feneley, 2009). Briefly, a hollow needle is inserted into the prostate 
via the wall of the rectum and removes 10 to 12 small cores of tissue (Eichler et 
al., 2006; Hara et al., 2008) which will be further analysed to give information 
concerning the grade and extension of the tumor. However, the absence of 
sufficient tissue for analysis and also the heterogeneous character of this 
disease may comprise a hurdle for distinguish whose glands are malignant from 
those who are benign (Epstein, 1995). 
 
 
7. Prognostic factors  
Besides PSA, grade and stage are the most usual prognostic factors for PC 
(Kattan et al., 1998; Epstein et al., 2006). The malignant potential of a certain 
neoplasia is determined by analysing the degree of differentiation exhibit by 
cancer cells. In 1966 Donald Gleason and collaborators proposed what is now 
the universal standard system for grading prostate carcinomas, which was 
recently updated by the International Society of Urological Pathology (ISUP) 
(figure 7) (Gleason, 1966; Gleason and Mellinger, 1974; Epstein et al., 2016).  
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The Gleason grading system is entirely based on the degree of histological 
deviation displayed by hematoxylin-eosin stained PC tissue sections under low 
to intermediate magnification. Five distinct patterns of grades can be assigned 
to the most (primary) and second-most (secondary) predominant patterns found 
in a tissue on a scale from one (well differentiated pattern) to five (poorly 
differentiated pattern) (Gottipati et al., 2012). Ultimately, the morphological 
heterogeneity perceived in the neoplasia can be evaluated by summing the 
primary and secondary grades and thus establish the final score. The Gleason 
score ranges from two to ten (Gleason and Mellinger, 1974). Briefly, Gleason 2 
to 6 tumors are considered to be well differentiated and thus possess a fairly 
good prognosis. Conversely, Gleason 7 to 10 tumors are less differentiated and, 
for that reason, associated to a poorer prognosis (Humphrey, 2004; Gottipati et 
al., 2012). 
 
Figure 7 | 2015 modified ISUP Gleason grading system. Five distinct patterns of grades can 
be attributed the two most dominant patterns found in the tissue. Pattern 1 matches closely-
packed, uniform, rounded to oval glands. Pattern 2 to more loosely arranged glands with 
smooth ends that minimally invade non neoplastic tissue. Patten 3 to irregular size and shape 
glands with more infiltrative margins. Pattern 4 to fused, cribriform or ill-defined glands. Finally, 
pattern 5 to almost no glandular differentiation (Epstein et al., 2016) 
 
One of the most important phases in the process of diagnosing a cancer is 
defining its extension or spread and, therefore, determining its behaviour, 
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choosing the most suitable therapy and predicting the resultant outcome. For 
most cancers the tumor, node and metastasis (TNM) staging system is the most 
widely used by clinicians (table 1) (Cheng et al., 2012). As the name implies, 
the system is organized in three main categories: a T (T1 to T4), an N (N0 or 
N1) and an M (M0 or M1) segment. The T describes the degree of extension of 
a primary tumor. Concisely, T1 and T2 refer to organ-confined neoplasms, 
whereas T3a and T3b symbolise extra-prostatic extension, with or without 
seminal vesicle invasion, respectively. Lastly, T4 tumors signify invasion of 
neighbouring organs (Yarbro et al., 1999). On the other hand, the N and M 
components specify whether or not a cancer had metastasized to the lymph 
nodes or distant sites, respectively. As soon as this process is completed a 
stage ranging from 0 (in situ) to IV (most advanced disease) can be assigned. 
 
 
Stage T N M PSA (ng/ml) GS 
 
I 
T1a-c N0 M0 <10 ≤ 6 
T2a N0 M0 <10 ≤ 6 
T1-2a N0 M0 X X 
 
 
IIA 
T1a-c N0 M0 <20 7 
T1a-c N0 M0 ≥ 10 and < 20 ≤ 6 
T2a N0 M0 <20 7 
T2b N0 M0 <20 ≤ 7 
T2b N0 M0 X X 
IIB T2c N0 M0 Any PSA Any Gleason 
T1-2 N0 M0 ≥ 20 Any Gleason 
T1-2 N0 M0 Any PSA ≥ 8 
III T3a-b N0 M0 Any PSA Any Gleason 
IV T4 N0 M0 Any PSA Any Gleason 
Any T N1 M0 Any PSA Any Gleason 
Any T Any N M1 Any PSA Any Gleason 
Table 1 | American Joint Committee on Cancer (AJCC) stage grouping (2010 edition). M 
(Metastasis), N (node), PSA (prostate-specific antigen) T (tumour), x (unknown) (adapted from 
Cheng et al., 2012). 
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Prognostic factors have been used to determine the risk of relapsing after 
therapy (D’Amico et al., 1998). In fact, the discrimination of patients into low, 
intermediate or high-risk groups (table 2) consents urologists the opportunity of 
selecting the treatment that better suits a certain tumour (Graefen et al., 2004; 
Greene et al., 2006; Damber and Aus, 2008). Nonetheless, this system is not 
flawless and, as such, the identification of novel diagnostic and prognostic 
biomarkers for a better therapeutic resolution is mandatory. 
 
Risk-group PSA level (ng/ml) GS Stage 
Low ≤ 10 ≤ 6 T1c to T2a 
Intermediate 10-20 7 T2b 
High ≥ 20 ≥ 8 T2c-3a 
Table 2 | Stratification of PC patients into distinct risks groups. Patients can be categorized 
into low-, intermediate-, and high-risk groups based on the serum level of PSA, GS, and stage 
(adapted from D’Amico et al., 1998 and Mottet et al., 2015). 
 
 
8. Treatment 
8.1. Treating localized neoplasms. 
One of the major struggles regarding the management of PC is the 
discrimination between men whose tumour is expected to remain quiescent 
from those who harbour aggressive neoplasms and thus require radical therapy 
(Attard et al., 2015). In the presence of low-risk tumours patients can be cured 
and face the option of either surgery or radiotherapy (Cooperberg et al., 2004; 
Galper et al., 2006; Bill-Axelson et al., 2011). The surgical removal of the 
prostate and seminal vesicles, also known as radical prostectomy (RP) (open 
laparoscopic, or robotic-assisted), comprises a high morbidity associated 
surgery involving ample economic burden to the healthcare system. Of every 38 
performed surgery only one case truly benefit from it, with the remaining 37 
reporting substantial short or long term adverse events, including sexual 
dysfunction and urinary incontinence (Sanda et al., 2008; Carter et al., 2015). 
This procedure is particularly recommended for males  whose life expectancy is 
greater than 10 years and whose comorbidities are low (Albertsen et al., 2011). 
SOX2 a master gene regulating progression in prostate cancer? 
33 
 
Generally, patients beyond 70 years of age are not suitable for surgery 
(Albertsen et al., 1998). 
Radiotherapy can be delivered by external-beam radiotherapy (EBRT), 
brachytherapy or, more recently, proton beam therapy (PBT), and can be used 
as monotherapy or combined as an adjuvant post-RP (DeVita et al., 2008; 
Heidenreich et al., 2016). In comparison to RP fewer side effects are reported, 
with both possessing similar survival rates (Jani and Hellman, 2003). ERBT 
embodies a conventional non-invasive approach that delivers beams of high-
energy x-rays to gland and surrounding milieu, including the seminal vesicles 
(Duchesne, 2001; Moule and Hoskin, 2009). Conversely, PBT resorts to protons 
as an alternative to x-rays to eliminate neoplastic cells. To date no clinical trial 
comparing ERBT to PBT is concluded. Yet, PBT appears to consent a superior 
control of the disease as well as dosimetry and toxicity advantages over 
conventional radiotherapy (Wisenbaugh et al., 2014). Brachytherapy refers to 
the inclusion of small radioactive seeds directly into the prostate, either 
permanently or temporarily, thus protecting the surrounding tissues from the 
effects of radiation (Moule and Hoskin, 2009). 
A prominent number of radically-treated tumours are being reported to be 
seemingly harmless (Cooperberg et al., 2011). For this reason, reducing 
overtreatment in men whose tumours do not pose a real harm and are likely to 
remain quiescent has become a priority for urologists (Loeb et al., 2014). The 
emergence of surveillance strategies, i.e., active surveillance (AS) or watchful 
waiting, offers patients the opportunity of escaping needless, possibly harmful 
treatment and refer to any approach that is used to delay or avoid therapy via 
surveillance after a positive diagnosis (Attard et al., 2015; Chung and Lee, 
2016). AS encompasses a management strategy involving close monitoring of 
the course of the disease by repetitive testing (Filson et al., 2015). As soon as 
early signs of progression start to be perceived curative intended therapy is 
introduced (Choo et al., 2012). Comparable to AS, watchful waiting also 
embroils meticulously monitoring of PC albeit the expectancy is to deliver 
palliative treatment once the manifestation of symptoms is imminent (Chung 
and Lee, 2016). 
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8.2. Treating advanced neoplasms 
In most patients PC presents itself as an organ-confined disease which can be 
effectively treated by surgical, radio, or surveillance options. Nonetheless, some 
eventually progress or present disseminated and incurable disease with the 
available treatments being merely palliative. The balance between cell 
proliferation and cell death is crucial for preserving the authenticity of tissues. In 
fact, deviations in the normal operation of these processes have been allied to 
the onset, progress and maintenance of a number of pathologic conditions, 
including cancer. Prostate carcinomas rely on androgens for growth and 
survival, i.e., androgens stimulate proliferation and inhibit apoptosis of cancer 
cells. Therefore, androgen deprivation therapy (ADT), either by chemical or 
surgical castration, emerged as the standard of care for advanced or recurrent 
PC (Harris et al., 2009). While surgical castration, or bilateral orchiectomy, 
eradicates testosterone by removing the testis, chemical castration is usually 
achieved by the use of luteinising hormone-releasing hormone (LHRH) agonists 
and antagonists. These drugs are able to diminish the amount of testosterone in 
circulation by blocking the pituitary synthesis of LH via mechanisms of negative 
feedback or competitive inhibition, respectively, and may be used in 
combination with surgical or radiation options (Perlmutter and Lepor, 2007; 
Ramsay et al., 2009; Heidenreich et al., 2011). Anti-androgens have also been 
used, i.e., flutamide, bicalutamide and nilutamide, and operate as competitive 
inhibitors thus avoiding the stimulation of the androgen receptor (AR) (Monnet 
et al., 2015).  
ADT produces a temporary therapeutic response that is usually followed by 
relapse and disease progression in one to two years, a status known as 
castration-resistant PC (CRPC). In these cohort the occurrence of metastatic 
CRPC (mCRPC) embraces the leading cause of death (Gupta et al., 2014). The 
molecular mechanisms underlying mCRPC are not entirely understood but 
largely reliant on the signalling governed by AR (Knudsen and Scher, 2009; 
Chandrasekar et al., 2015). The acquisition of numerous genetic alterations 
leading to AR amplification, binding of alternative AR ligands, intratumoral 
steroidogenesis, and enhanced activity of several pathways, including the 
Wnt/β-catenin signalling are some of the related mechanisms (Chandrasekar et 
al., 2015; Katzenwadel and Wolf, 2015). As such, several research teams are 
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now focused on developing strategies to block AR and their immediate 
downstream targets. Indeed, the management of mCRPC, i.e., administration of 
docetaxel plus prednisone (Carles et al., 2012) is being strongly modified due to 
the development of novel medicines that ultimately improve overall survival 
rates (Gilson et al., 2015). They include the two next-generation AR targeting 
abiraterone acetate and enzalutamide but also the sipuleucel-T vaccine, 
carbazitaxel, and radium 223 (Kantoff et al., 2010; Fizazi et al., 2012a; Fizazi et 
al., 2012b; Sher et al., 2012; Parker et al., 2013). However, and regardless of 
such improvements, survival rates remain low, with the average standing in 3.5 
years (James et al., 2015).  
Overall, currently available PC therapies significantly interfere with the patient 
wellbeing and thus the development of novel diagnostic and therapeutic tools is 
extremely mandatory. 
 
 
9. Role of the stemness SOX2 gene in prostate cancer. 
9.1. SOX2, a stem cell transcription factor. 
A group of stem cell reprogramming factors is emerging as oncogenes in a 
myriad of cancers (Jeter et al., 2009; Karoubi et al., 2009). Their expression is 
capable of prompting large scale alterations in both gene expression and cell 
behaviour, raising the question of whether or not stemness signatures intervene 
in malignant transformation (Takahashi et al., 2006). Likewise, insights into their 
expression and function in cancer is paramount to better understand the 
mechanistic underlining its development. 
The core embryonic stem cell transcription factor machinery is comprised by 
distinct factors whose orchestration is essential for maintaining pluripotency and 
preventing adequate cell differentiation (Chambers, 2009). Indeed, several 
studies reported that not only stemness genes support cell survival and 
proliferation, but also interfere with regular differentiation processes. Thus, it is 
feasible to contemplate that they are capable of promoting hallmarks of 
tumorigenesis and disease progression via mechanisms resembling their role in 
stemness cells (Ye et al., 2008). In 1990 the mammalian testis-determining 
factor (Sry) gene on the Y-chromosome (Sinclair et al., 1990) was discovered. 
This gene is characterized by the presence of a highly conserved high-mobility 
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group (HMG) domain whose function relies on deoxyribonucleic acid (DNA) 
recognition and binding. Proteins with amino acid similarity of 50 percent or 
higher to the Sry HMG domain are termed SOX. In the vertebrate genome the 
SOX family is composed by 20 distinct members which, based on HMG 
sequence homologies, are further distributed throughout eight subfamilies (Cao 
et al., 2015). Furthermore, they lack adequate affinity for DNA binding and thus 
require the recruitment of protein partners, including Nanog, OCT4, and Sall4 
(Otsubo et al., 2008). In human, the SOX2 gene is positioned in the 
chromosome 3 and comprises three main domains: an N-terminal, a HMG, and 
a transactivation domain (figure 8) (Weina and Utikal, 2014). 
 
 
Figure 8 | SOX2 homology, structure, and protein function. SOX2 belongs to the SOXB1 
group of SOX proteins. The elements of these group share large homology due to the fact that 
they all possess the N-terminal, the HMG, and the C-terminal domains (Weina and Utikal, 
2014). 
 
Data on the literature deeply envisage the pivotal role of SOX2 in embryonic 
stem cells pluripotency and self-renewal properties maintenance (Masui et al., 
2007; Adameyko et al., 2012; Sarkar and Hochedlinger, 2013). In addition, 
SOX2 is one of the master transcription factors responsible for reprogramming 
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differentiated somatic cells to induced pluripotent stem cells (iPSCs) (Sarkar 
and Hochedlingerm, 2013). More recently, numerous efforts have been made in 
order to establish the link between SOX2 and malady, particularly cancer. In 
fact, several lines of evidence highpoint that SOX2 is deregulated in a variety of 
cancers, and capable of disturbing the physiology of cancer cells via 
involvement in intricate signalling pathways and protein-protein interactions 
(Weina and Utikal, 2014). However, the molecular network sustained by this 
transcription factor and the resultant clinical pathological outcome has not been 
well documented. 
 
 
9.2. Role of SOX2 in the development and progression of prostate cancer. 
SOX2 is expressed in the basal compartment of both normal and neoplastic 
epithelium of the prostate (Jia et al., 2011; Ugolkov et al., 2012; Russo et al., 
2015). Importantly, it has been postulated that the expression of SOX2 in 
neoplasia is significantly deregulated. Indeed, the published outcomes 
concerning expression of SOX2 in diseased versus normal prostate are 
conflicting. While one discloses that the expression of SOX2 diminishes 
significantly in organ-confined PC via gene promotor methylation (Russo et al., 
2015), others found SOX2 to be overexpressed in cancerous tissue (Jia et al., 
2011). Notably, it appears that SOX2 expression is correlated with the clinical 
progress of PC, i.e., strong expression of SOX2 was uniquely perceived in 
tissues with augmented histologic grade and Gleason score (Jia et al., 2011). 
Analysis of p63 and Pten-null mice reveals that basal expression of SOX2 
contributes to the luminal population and enhances tumorigenesis (Wang et al., 
2014). SOX2 was also found to promote tumorigenesis and survival by 
sustaining the epidermal growth factor receptor (EGFR)-mediated self-renewal 
of stemness PC cells. In essence, EFGR signalling enhances SOX2 expression 
whereas SOX2 knock-down results in EGFR signalling eradication (Rybak and 
Tang, 2013). Moreover, SOX2 governs the expression of cyclin E, p27, and 
survinin (Lin et al., 2012) and it is involved in paclitaxel resistance of the PC3 
cell line via the PI3K/Akt pathway (Li et al., 2014). 
SOX2 is emerging as a powerful prognostic tool to predict cancer progression 
and cancer-specific survival in patients with metastatic PC (Fujimura et al., 
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2014). Experimental models proposed SOX2 as an AR repressed gene, 
capable of promoting the emergence of CRPC phenotypes (Kregel et al., 2013). 
In fact, the inhibition of AR via enzalutamide treatment is responsible for 
prompting a robust increase in the expression of SOX2 (Kregel et al., 2013). 
Moreover, upregulation of SOX2 in the LNCaP cell line is seen concomitantly to 
ADT resistance (Seiler et al., 2013; Wang et al., 2014). SOX2 overexpression 
stemmed resistance to the depletion of androgens and facilitated the 
establishment of xenograft tumours in castrated mice (Seiler et al., 2013). 
Indeed, the number of SOX2+ cells after progression and metastasis was found 
to be enlarged (Kregel et al., 2013). Such increase was seen as part of a 
reprogramming of primarily non-metastatic PC cells, which attained the potential 
to colonize and grow in bone. Nonetheless, the precise role of SOX2 and 
whether or not it might be modulated in PC bone metastasis is poorly 
understood.  
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AIMS 
 
 
The prevalence of PC in man is very high. The probability of obtaining a biopsy 
positive for prostate carcinoma within a given population has been estimated to 
be around 30 percent. A Gleason score is established taking into account 
histopathological criteria. Although of prognostic value it does not distinguish 
those tumours which would benefit from aggressive therapy from those which 
would be of no real harm to the patient on the long run (Attard et al., 2015) 
The present study aimed to investigate the effects of SOX2, a stem-cell 
associated transcription factor in order to better understand whether it might 
play a putative role during PC progression. Thus, our specific objectives in order 
to evaluate the effect of SOX2 inhibition in the biological behaviour of PC cell 
lines were: 
 
 
a) To assess SOX2 expression in several PC cell lines cultured in vitro 
assembled into a tissue microarray by immunohistochemistry and in human PC 
cell lines:  
• Fluorescence analysis 
• Western blot analysis 
 
 
b) To ascertain the role of SOX2 in PC progression by assessing the effect of 
SOX2 knock-down with siRNAs in in vitro studies: 
 Cell morphology 
 Apoptosis 
 Migration capacity, wound-healing 
  
 
c) To assess SOX2 pattern of expression in a human PC series comprised 
exclusively of Gleason 8 and 9 graded cancer cases 
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MATERIALS AND METHODS 
 
 
1. Prostate Cancer Tissues  
 
Patients 
 
PC samples were obtained from patients submitted to surgery at the Centro 
Hospitalar São João, Porto. Both incisional and excisional biopsies were 
removed and fixed in 10% neutral buffered formalin. After being dehydrated and 
embedded in paraffin, a section of 3 µm was obtained from each representative 
paraffin block for staining with hematoxylin and eosin and 
immunohistochemistry. 
 
 
2. Cell lines and culture conditions  
 
PNT2, PNTA1, 22RV1, DU145, MDA-PCa-2b, LNCaP, VCaP, RWPE-1 and 
PC3 cell lines, kindly provided by Professor Manuel Teixeira, IPO, were used in 
initial studies (Table 3 and 4). Cells were cultured at 37ºC in a humidified 5% 
CO2 incubator (Thermo Scientific) and maintained in complete media 
supplemented with 10% of fetal bovine serum (FBS) (Gibco Life Technologies) 
and 1% Penicillin Streptomycin (Gibco Life Technologies) for a confluence of 70 
to 80%. PNT2 and 22RV1 cell lines were cultured in RPMI 1640 (Gibco Life 
Technologies) and PC3 cells in F12 medium (Gibco Life Technologies). Re-
plating of cells was accomplished by using trypsin followed by resuspension of 
cells into fresh medium.  
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Table 3 | Main characteristics of human prostate cell lines. All these cell lines are androgen 
independent. 
 
Line 
 
 
Type 
 
Origin and Tumorigenicity 
PSA 
expression 
 
 
 
PNT2 
 
 
 
Epithelial; adherent 
 
 
The primary culture was derived from a 
prostate of a 33-year-old male at post mortem. 
The cells are non-tumorigenic in nude mice. 
 
 
 
 
 
N/A 
 
 
PNTA1 
 
 
Epithelial 
Adherent 
 
The primary culture was derived from a 
prostate of a 33-year-old male at post mortem 
The cells are non-tumorigenic in nude mice. 
 
 
 
N/A 
 
 
DU145 
 
Carcinoma; 
epithelial; adherent 
 
 
Established from a brain metastasis of a 69-
year-old Caucasian male. 
The cells are tumorigenic in nude mice 
 
 
- 
 
 
PC3 
 
Grade IV 
adenocarcinoma; 
epithelial; adherent 
 
 
Initiated from a bone metastasis of a grade IV 
prostatic adenocarcinoma from a 62-year-old 
Caucasian male. 
The cells are tumorigenic in nude mice. 
 
 
 
- 
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Table 4 | Main characteristics of human prostate cancer cell lines.  All these cell lines are dependent 
of androgens. 
Line Type Origin and Tumorigenicity PSA 
expression 
 
 
22RV1 
 
Carcinoma
Epithelial 
Adherent 
 
Established from a xenograft that was 
propagated in mice after castration-induced 
regression and relapse of the parental, 
androgen-dependent CWR22 xenograft. The 
cells are tumorigenic in nude mice. 
 
 
 
 
 
+ 
 
MDA-
PCa-2b 
 
Adenocarci
noma 
Epithelial 
Adherent 
 
Derived from a bony metastasis of an 
androgen-independent carcinoma of a Black 
male with 63 years of age. 
The cells are tumorigenic in nude mice. 
 
 
 
 
 
+ 
 
LNCaP 
(clone 
FGC) 
 
Carcinoma 
Epithelial 
Adherent. 
 
Initiated from a left supraclavicular lymph 
node metastasis of a Caucasian male with 50 
years of age collected from a needle 
aspiration biopsy. 
The cells are tumorigenic in nude mice. 
 
 
 
 
+ 
 
 
VCaP 
 
 
Epithelial 
adherent 
 
Established from a vertebral bone metastasis 
from a 59 year-old Caucasian men CRPC 
diagnosed. 
The cells are tumorigenic in nude mice. 
 
 
 
+ 
 
RWPE-
1 
 
Epithelial 
Adherent 
 
The cells were established from a normal 
human prostate of a 54 years old male 
 
 
+ 
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3. Tissue microarray construction 
 
Nine PC cell lines were arrayed in duplicates into one tissue microarray (TMA) 
block. The first requirement for construction of the TMA is to obtain a large 
number of cells cores. Likewise, each cell line was grown and collected from 
culture flasks by scrapping. Afterwards, cells were washed three times with 
phosphate buffered saline (PBS), ressuspended in 10% Neutral-buffered 
formalin and fixed for 1 hour in gently agitation. The cell pellet was processed 
with the Thermo Scientific Richard-Allan Scientific HistoGelTM (Thermo 
Scientific). Briefly, the HistoGel must be liquefied by heating in a water bath. 
Each cell pellet was embedded in the liquefied gel and vortex to allow effective 
mixing. The samples were refrigerated at -20ºC to allow complete solidification 
and transferred to a cassette. Following overnight fixation, the samples were 
processed, embedded in paraffin, sectioned and haematoxylin-eosin stained. 
The Beecher manual tissue microarrayer (Manual Tissue Arrayer, Beecher 
Instruments, Inc, Wisun, USA) was used to construct the TMA. A core of tissue 
was removed from a donor block and implanted into a recipient block following 
a previously established order. Non-neoplastic tissue from the prostate as well 
as mammary cancer cell lines were included as control. Once this process was 
completed, the recipient block was melted to promote the binding of the cores 
with the block. Melting was performed by overnight incubation at 37ºC. In the 
next day, the blocks were submitted to cycles of resting plus incubation at 37ºC 
for 1 hour. This process was repeated twice. Afterwards, the TMA block was 
incubated at 60ºC for homogenization of its surface and sectioned into 2 to 3 
µm tissue sections in coated glass slide (Superforst Plus, Gerhard Menzel, 
Braunschweig, Germany). 
 
 
4. Immunohistochemistry 
The expression of SOX2 was assessed in paraffin-embedded PC samples and 
the assembled TMA by immunohistochemistry following a standard protocol. 
Briefly, the slides were deparaffinised in xylene and rehydrated in an 
alcohol/water gradient. Antigen retrieval was performed in 
ethylediaminetetraacetic (EDTA) for 40 minutes following a resting period of 20 
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minutes at room temperature. The activity of endogenous peroxidase was 
blocked by incubating the sections in 3% hydrogen peroxide (H2O2) for 10 
minutes. Afterwards, sections were incubated overnight at 4ºC with monoclonal 
anti-SOX2 (1:50 dilution, SP76 clone, Cell Marque, Rocking, CA, USA), washed 
in tris-buffered saline-tween 20 (TBS-T) and developed using the Dako REAL™ 
Envision™ Detection System Peroxidase/DAB + (Envision-DAKO, Glostrup, 
Denmark). The reaction was developed using 3,3′-
diaminobenzidinetetrahydrochloride (DAB) (Sigma, St. Louis, MO, USA) 
according to the manufacturer’s instructions. Sections were then counterstained 
with haematoxylin, dehydrated and mounted using histologic mounting media 
(Thermo Scientific Richard-Allan). All stained sections were examined using a 
Zeiss Optical Microscope and reviewed by two observers. 
 
5. Protein extraction and Western Blot 
Cells were scrapped and washed with PBS 3 times at 4ºC. Next, cells were 
incubated with lysis buffer (RIPA (20 mM Tris, pH7.2, 10mM EDTA, 0.3 M 
NaCL, 0,1% Triton X-100, 0,005% Tween-20), protease inhibitors (1 mM phenyl 
methyl sulfonyl fluoride (PMSF), 1 mM sodium orthovanadate (Na3VO4) and 
complete protease inhibitor cocktail (Roche Applied Science)) on ice for 30 
minutes. The lysates were centrifuged for 15 minutes at 12000 G, the 
supernatants collected, and the protein content quantified using the BCA 
Protein Assay Reagent (Thermo Scientific, USA), according to the 
manufacturer’s instructions. Proteins were run on Mini-PROTEAN TGX 4-20% 
gels (Bio-Rad, USA) and transferred by electro blotting to nitrocellulose 
membranes (Amersham, Biosciences). The membranes containing the proteins 
were blocked with 5% non-fat dry milk diluted in TBS (50mM Tris, pH 7.6, 
150mM NaCl, 0,005% Tween 20) and incubated with agitation at 4ºC overnight  
with anti-SOX2 (1:500 dilution, Cell Maque, Rockling, CA, USA) and anti-actin 
(1:4000, Santa Cruz Biotecnology) diluted in 5% non-fat dry milk in TBS. In the 
day after, the membranes were washed with TBS-tween and incubated with the 
secondary antibody goat anti-rabbit (1:2000 dilution, DAKO) at room 
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temperature for 1 hour. Immunolabeling was performed by using the enhanced 
chemiluminescence reagent (ECL; Amersham Biosciences).  
 
 
6. Fluorescent immunocytochemistry 
PC3 cells were cultured in glass coverslips for approximately 24 hours. Cells 
were washed with PBS and fixed with cold methanol for 30 minutes. Following 
fixation, cells were re-hydrated with PBS and incubated with normal rabbit 
serum in PBS with 10% bovine serum albumin (BSA) for 20 minutes to block 
nonspecific staining. Next, sections were incubated with primary antibody for 
SOX2 (1:50 dilution, SP76 clone, Cell Maque, Rockling, CA, USA) in PBS with 
5% BSA overnight at 4ºC. After washing, the slides were incubated with 
secondary goat anti-rabbit antibody (1:100 dilution, DAKO) for 45 minutes, 
washed twice, incubated with 4',6-diamidino-2-phenylindole (DAPI) (Sigma-
Aldrich, USA) for 15 minutes. For fluorescence analysis, slides were mounted in 
Vectashield mounting medium (Vector Laboratories, USA) and analysed in a 
Carl Zeiss fluorescent microscope (Carl Zeiss Microscopy, Germany). 
 
 
7. Transient transfection assays: inhibition of SOX2 by siRNAs 
PC3 cell line was transfected with a commercial set of three small interference 
ribonucleic acid (siRNA) duplexes targeted against human SOX2 
(#HSS144045: sense 5’-GCGUGAACCAGCGCAUGGACAGUUA-3’; 
#HSS186041: sense 5’-CCUGUGGUUACCUCUUCCUCCCACU-3’; 
#HSS186042: sense 5’-CCAAGACGCUCAUGAAGAAGGAUAA-3’; Invitrogen, 
Life Technologies, Carlsbad, CA, USA) or scrambled controls (1: sense 5’-
GCCGAAAUGGCGACGUCCAGAAUAU-3’; 2: sense 5’-
GCGCAGCGAAGUCGGUCGAUACGU-3’; 3: sense 5’-
GAUGCGGACGGAGGAUCHAUGUCA-3’, Invitrogen, Life Technologies, 
Carlsbad, CA, USA). The cell line (6x105) was firstly seeded into six well plates. 
In the following day the inhibition of SOX2 was performed with each well 
containing 1.67 µl of either scrambled controls or siRNA duplexes. Master 
mixes for each transfection condition were prepared. Four distinct tubes were 
prepared to which we added (i) 1.67 µl of the plasmid DNA (ii) 1.67 µl of the 
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universal control (iii) and (iv) 5 µl of Lipofectamine 2000 reagent (Invitrogen), 
plus 125 µl of Opti-MEM Reduced Serum Media (Invitrogen). After 10 minutes 
of incubation at RT, the contents of tubes (iii) and (iv) were added to the first 
ones, mixed gently and incubated for 20 minutes at room temperature. The cells 
were washed with phosphate-buffered saline (PBS) and 750 µl of Opti-MEM 
plus 250 µl of the complex mixture were pipetted carefully to each well. The 
plates were mixed by shaking and incubated at 37ºC for approximately 24 
hours. The culture medium was changed to standard medium and the cells 
collected in the next day. 
 
 
8. Wound-healing Assay 
The wound-healing assay was carried out in a time-lapse microscope and 
image acquisition was performed for 18 hours. Briefly, 3 x 105 cells were plated 
in triplicates in 24 wells culture plate for a confluence of 100%. An artificial 
wound was done by scratching each well with a pipette tip. The culture medium 
was replaced by fresh medium and the migration rate of cells was assessed 
considering their healing capacity for 18 hours. 
 
 
9. Annexin V/PI Assay 
Each cell line was harvested and transfected according to the previously 
conditions described. Cells were pelleted by centrifugation, the culture medium 
was complete removed, and cells were ressuspended in 400 µl of binding buffer 
(Annexin V Apoptosis detection kit, eBioscience, San Diego CA, USA). 195 µl of 
each sample was aliquot and firstly stained with 5 µl of annexin V for 10 minutes 
and then with 10 µl of propidium iodide (PI). The incubations were performed at 
room temperature in the dark. The percentage of apoptotic cells was measured 
in the flow cytometer BD Accuri C6 (BD Biosciences, San Diego CA, USA). 
 
 
10. Statistical analysis 
Whenever adequate, the results were presented as mean ± standard deviation. 
Statistical analysis was performed using One Way ANOVA (Analysis of 
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variance) test and for multiple comparisons Dunnett and Tukey’s tests with 
p<0,05 as the level of significance, in GraphPad Prism 5.02 version. 
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RESULTS 
 
Androgen receptor positive vs negative human prostate cancer cell lines 
morphology 
 
PNT2 is a human epithelial normal prostate cell line, whereas PC3, DU145 and 
22RV1 comprise human PC cell lines.  
PC3, DU145 and PNT2 are three well-established AR negative human PC cell 
lines. In morphologic terms, DU145 cells appear more circular and smaller in 
comparison to the highly metastatic PC3 cell line. The later further displays a 
dendritic-like morphology. In the case of PNT2 cell line, it mostly resembles the 
appearance of DU145 cells. However, the shape of PNT2 cells appears less 
circular and the cells are capable of establishing a few more processes. 
Furthermore, the PNT2 line possess a slightly larger cell size than DU145 cells 
(figure 9). 
22RV1 is an AR positive human PC cell line. Regarding its morphologic 
features, and in comparison to the previously described cell lines, it exhibits a 
more polygonal shape and the cells growth appears more clustered. In addition, 
22RV1 cells are smaller than PC3 cells (figure 10). 
 
 
Figure 9 | Phase contrast microscopy pictures of human androgen independent cancer and normal 
prostate cell lines. Pictures of the highly metastatic PC3 (A), moderately metastatic DU145 (B) and 
normal PNT2 (C) cell lines. Cellular morphology was inspected using a Zeiss inverted microscope at 10x 
magnification (Scale = 100 µm) 
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Figure 10 | Phase contrast microscopy pictures of the human AR positive PC 22RV1 cell line. 
Cellular morphology was inspected using a Zeiss inverted microscope at 10x magnification (Scale = 100 
µm). 
 
 
Androgen receptor positive and negative human prostate cancer cell lines 
TMA assembly   
 
The TMA comprises an extremely versatile methodology that consents large 
scale measurements of either ribonucleic acid (RNA) or protein expression in 
various sections of tissue simultaneously (Kononen et al., 1998). The 
construction of TMA blocks is generally made from tissues embedded in 
paraffin. Nevertheless, novel methods that enabled the construction of TMAs 
from small volumes of cells in suspension were developed (Waterworth et al., 
2005). The whole technique is performed in a centrifuge tube and produces an 
outstanding preservation of both cytomorphology and immunoreactivity of the 
cellular cores included in the TMA block, contrarily to what would occur in 
cytospins. The latter is often used to restrain cells onto glass slides for staining 
procedures. However, it generally prominently affects the quality and 
morphological features of the cell prep (Methods in Enzymology, 2013). 
We started by selecting the most representative areas of each cell core, 
previously separately embedded in paraffin, using hematoxylin-eosin staining. 
Afterwards, each cell core was transferred in duplicates to a recipient block, 
following a defined array of coordinates previously established in an excel 
datasheet (figure 11), to better capture the heterogeneity of each core.  To 
include all samples, i.e., controls and nine prostate cell lines, one tissue array 
was constructed. As described in figure 11, non-neoplastic tissue of the normal 
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prostate was included as positive control in position 1. Mammary cancer cell 
lines were included in positions 28, 29, 30, 33 and 34 also for control purposes. 
The remaining positions were occupied by normal and cancer cell cores of the 
prostate as well as paraffin to assure the stability of the block during sectioning. 
Multiple 3 µm sections were cut and stained by a specific antibody for 
immunohistochemistry analyses. 
 
 
 
 
 
Prostate Paraffin Paraffin Paraffin Paraffin Paraffin Paraffin 
Paraffin PC3 (1) PNT2 (1) 
MDA-
Pca-2b 
(1) 
VCaP (1) 
RWPE-1 
(1) 
RWPE-1 
(2) 
Paraffin PC3 (2) PNT2 (2) 
MDA-
Pca-2b 
(2) 
VCaP (2) CMM115 
CMA07 
(1) 
Paraffin 
22RV1 
(1) 
DU145 
(1) 
LNCaP 
(1) 
PNT1a 
(1) 
CMM26 
CMA07 
(2) 
Paraffin 
22RV1 
(2) 
DU145 
(2) 
LNCaP 
(2) 
PNT1a 
(2) 
CMTU27 Paraffin 
 
Figure 11 | Construction of the PC cell lines TMA block. A TMA grid was firstly generated in an Excel 
data sheet containing the coordinates of the block and the cell cores identification. Normal prostate tissue 
as well as mammary cancer cell lines were included as controls.  
 
 
SOX2 expression in the Androgen Receptor positive and negative human 
prostate cancer cell lines TMA 
 
All prostate cell lines were almost negative. PC3 cell line was lightly positive, 
when compared with the positive control; basal cell lines of the normal human 
prostate tissue as well as mammary cancer cells were included as controls 
(figure 12, 13 and 14). 
 
 
 
TMA prostate cancer cell lines 
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Figure 12 | Macroscopic pictures of the PC cell lines TMA block and sections. The image shows 
hematoxylin & eosin and SOX2 stained sections and the paraffin embedded cell cores block. Normal 
human prostate tissue as well as mammary cancer cells were included as controls. 
 
 
 
   
   
PC3 PNT2 
MDA-PC1-2b VCaP 
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Figure 13 | Haematoxylin & eosin sections in PC cell lines assembled in the TMA. 
 
 
   
           
RWPE-1 22RV1 
LNCaP PNT1a 
DU145 
PC3 PNT2 
MDA-PCa-2b VCaP 
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Figure 14 | Expression of SOX2 in PC cell lines assembled in the TMA by immunohistochemistry. 
All prostate cell lines were negative with the exception of PC3 which was lightly positive.  Normal human 
prostate tissue as well as mammary cancer cells were included as controls (data not shown). 
 
 
SOX2 expression in prostate tumor cell lines. 
The expression level of SOX2 in the PC3 cell line was confirmed by Western 
Blot analysis and fluorescent immunocytochemistry. PNT2 and 22RV1 were 
included as negative controls. The 3D6 colon cancer cell line was used as a 
positive control. As indicated in figure above expression of SOX2 was only 
detected in PC3 cell line pointing to a possible involvement of SOX2 in the 
tumorigenesis of PC3 cells (figure 15).   
 
  
RWPE-1 22RV1 
 LNCaP PNT1a 
DU145 
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Figure 15 | SOX2 expression in prostate tumor cell lines by Western blot analysis. SOX2 protein 
expression is significant in PC3 cell line and non-detectable in PNT2 and 22RV1 cell lines. The 3D6 colon 
cancer cell line was used as a positive control. 
 
 
Regarding immunocytochemistry on methanol-fixated PC3 cells, despite most 
cells being negative, a few cells were strongly positive (red fluorescence). 
Subcellular localization points to a predominantly nuclear and/or cytoplasmic 
expression of SOX2 in this cell line (figure 16).  
 
 
Figure 16 | SOX2 protein expression in the PC3 cell line by immunocytochemistry. The majority of 
cells do not show SOX2 protein expression. Only a few cells were strongly positive for SOX2 (red 
fluorescence) and are predominantly positioned in the nucleus and/or in the cytoplasm. 
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Down-regulation of SOX2 in prostate derived cell lines 
In order to perform down-regulation experiments of SOX2 in neoplastic settings, 
we used metastatic PC3 cell lines which were cultured for 48 hours in siSOX2 
or scrambled conditions (normal PNT2 cell lines were included for further assay 
control purposes). Protein expression of SOX2 was determined by Western Blot 
analysis. As shown in figure 17 the expression of SOX2 was diminished in 
protein extracts from PC3 cells where siRNAs were used when compared to the 
scrambled transfected cells thus confirming the efficiency of the transfection 
experiments. Thus, SOX2 targeting siRNAs effectively knocked-down its 
expression in PC3 cells.  
  
Figure 17 | SOX2 expression in prostate tumor cell lines transfected with siSOX2 and 
scrambled controls by Western Blot analysis. SOX2 protein expression decreases in protein 
extracts from PC3 cells transfected with siRNA’s for SOX2 when compared to scrambled 
controls. In PNT2 protein extracts the expression of SOX2 remained non-detectable so we use 
this as cell as a control for the experiments (data not shown). 
 
 
Effect of SOX2 knockdown on the morphology of PC3 cells 
Cell clustering and morphology in PC3 cell lines before transfection with siSOX2 
showed no major differences when compared with cell clustering and 
morphology in PC3 cell lines transfected with siSOX2. The slight differences 
found occasionally were attributed to culture conditions (time, cell confluence) 
(figure 18). 
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Figure 18 | Contrast phase microscopic pictures of PC3 cells pre- and post- transfected with 
siRNAs for SOX2 or scrambled controls. No major differences were detected in clustering and 
morphology parameters when the PC3 cell line (A) was transfected with siSOX2 (B) when compared to 
scrambled controls (C). 
 
 
 
Effect of SOX2 knock-down in programmed cell death of PC3 cell line. 
The influence of SOX2 silencing on programmed cell death was evaluated by 
the in vitro assays below. To assess the effect of SOX2 silencing on the PC3 
cells line programmed cell death the Annexin V/PI assay was performed. To this 
end, we cultured cells under silencing and scrambled conditions for 48 hours. 
A 
B 
C 
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As previously shown, expression of SOX2 in the normal PNT2 cell line was not 
detectable by Western Blot. As such, we used this cell line as an internal control 
for the experiment. We found that forty-eight hour SOX2 silencing significantly 
increased the percentage of apoptotic cells of PC3 (p=0.0115) and not PNT2 
(p=0.6194) cell lines when compared to scrambled controls for SOX2 silenced 
cells. These results suggest promotion of programmed cell death of the PC3 
cell line by SOX2 inhibition (figure 19).  
 
 
 
 
Figure 19 | Percentage of apoptotic PC3 and PNT2 cells after 48 hours treatment with siRNAs for 
SOX2 and scrambled controls. SOX2 knockdown mediated by siRNAs significantly increased 
programmed cell death for the PC3 cell line (p=0.0115) and not for the PNT2 cell line (p=0.6194). 
 
 
 
 
 
Effect of SOX2 knockdown on migration capacity of PC3 cell line 
In order to investigate the effect of SOX2 silencing on the migration capacities 
of prostate tumor cells, wound-healing assays were performed. The knockdown 
of SOX2 expression in the PC3 cell line decreased cellular migration, as proven 
by an increase in the time required to close the artificial wound when compared 
to scrambled controls (figure 20). The migration rate decrease was statistically 
significant (p<0.01) using the T-test for the PC3 cell line. No differences were 
observed in the rates of cell migration for the PNT2 line after silencing SOX2 
                                            scrambled PC3            siSOX2 PC3            scrambled PNT2         siSOX2 PNT2 
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(figure 21). Thus, our results indicate that the migrating ability of PC3 cells is 
impaired upon SOX2 knockdown. 
 
 
 
 
Figure 20 | Wound-healing assay in PC3 cell line transfected with siSOX2 or scrambled 
control. Cells transfected with siSOX2 moved slower for closing the artificial wound when 
compared with cells transfected with scrambled controls. This decrease in migration rates was 
statistically significant (p<0.01). The results were obtained by time-lapse microscopy for 18 
hours. 
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Figure 21 | Wound-healing assay in PNT2 cell line transfected with siSOX2. No 
considerable alteration in the migration rate of cells transfected with siSOX2 and scramble for 
closing the artificial wound was observed. The results were obtained by time-lapse microscopy 
for 18 hours. 
 
 
Evaluation of SOX2 expression in a Gleason 8 and 9 PC series 
In order to investigate if SOX2 would relate to a specific aggressive cell subtype 
in invasive PC cells, a small series of Gleason 8 and 9 human PC samples was 
examined by immunohistochemistry. SOX2 was expressed in basal-like cells 
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both in primary tumors and normal-adjacent tissue (figure 22). These results 
further point to a role of SOX2 possibly associated to cancer aggressiveness. 
 
 
A 
 
 
B 
 
Figure 22 | SOX2 expression in Gleason 8 and 9 PC series by immunohistochemistry. 
Panel A and B shows the positive and negative pattern of expression of SOX2, respectively, in 
PC samples. 
 
In order to assess the link between SOX2 expression and PC tumorigenesis we 
proceeded to a statistical analyses focusing on SOX2 relationship with a series 
of clinical and histopathological guidelines described in table 5 and 6. We 
stratified patients onto two categories based on SOX2 negativity (N=0) and 
positivity (N≥1) of PC specimens. Hence, the clinical pathological outcomes 
were compared between samples with and without SOX2 staining; a total of ten 
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patients who underwent surgery were analysed with five cases (50%) in the N0 
category and the remaining five (50%) in the N1 category. We found no 
significant correlation between SOX2 expression, and tumor size (p=1) or 
Gleason score (p=0,141112); both SOX2 negative and positive tumors fall into 
either T1 or T2 and displayed a Gleason of 8 and 9. Nevertheless, in what 
regards the status of regional lymph nodes (N) we found that SOX2 negativity is 
closely associated to the presence of metastases in the lymph nodes (p<0,01). 
However, when we compared SOX2 positive and negative tumors regarding 
recurrence criteria, i.e., D’Amico risk, disease and disease-free survival, we 
found that SOX2-positive tumors were significantly associated to an increased 
D’Amico risk in comparison to SOX2 negative tumors (p=0,0399698524). 
Furthermore, we also denoted a statistical tendency and as such a possible 
correlation between SOX2 and disease-free survival (p=0,06775149). Indeed, 
SOX2-positive tumors possessed shorter disease-free survival duration. 
However, the results did not reach statistical significance. Nevertheless, these 
data point to a probable SOX2 involvement in tumor recurrence.  
In what concerns overall PC survival periods, no statistical differences were 
found (p= 0,662875818). Finally, a possible relationship between SOX2 
expression and the basal PSA was also addressed. We found no statistical 
correlation between SOX2 and PSA, though SOX2 positive tumors were 
apparently associated with increased levels of PSA (p=0,208109336).
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Table 5 | Clinical pathological data of the PC samples used in this study by SOX2 negativity (pN0), n=5 prostate carcinomas.  Several criteria were used in order to 
ascertain a possible relationship between SOX2 and PC, including stage, D’Amico risk, disease-free survival (PR_SV free) and disease survival (PR_SV), PC overall survival 
(PC_SV), size of the tumor (T), regional lymph node (N) and bony (M) metastasis, Gleason score after RP (GPR) and basal PSA. 
 
Case 
 
SOX2 
 
State 
 
Stage 
 
D’Amico 
risk 
 
D’Amico 
risk p 
 
PR_SV 
free 
 
PR_SV 
 
PC_SV 
 
T 
 
N 
 
M 
 
GRR 
 
PSA 
basal 
 
2420/95B3 
 
0 
 
3 
 
2 
 
2 
  
1 
 
1 
 
11 
 
33 
 
1 
 
0 
 
9 
 
9.9 
 
8220/01 B27 
 
0 
 
3 
 
1 
 
2 
 
3 
 
127 
 
127 
 
135 
 
33 
 
1 
 
0 
 
9 
 
16 
 
6894/01 B28 
 
0 
 
0 
 
1 
 
2 
 
2 
 
85 
 
85 
 
142 
 
23 
 
1 
 
0 
 
9 
 
18.4 
 
10709/01 35 
 
0 
 
0 
 
1 
 
2 
 
3 
 
98 
 
98 
 
141 
 
33 
 
1 
 
0 
 
9 
 
14.7 
 
H05/13469 
B24 
 
0 
 
0 
 
1 
 
2 
 
3 
 
78 
 
79 
 
89 
 
32 
 
1 
 
0 
 
9 
 
6.4 
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Table 6 | Clinical pathological data of the PC samples used in this study by SOX2 positivity (pN≥1), n=5 positive carcinomas. Several criteria were used in order to 
ascertain a possible relationship between SOX2 and PC, including stage, D’Amico risk, PR_SV free and PR_SV, PC_SV, T, N M, GPR and basal PSA. 
 
Case 
 
SOX2 
 
State 
 
Stage 
 
D’Amico 
risk 
 
D’Amico 
risk p 
 
PR_SV 
free 
 
PR_SV 
 
PC_SV 
 
 T 
 
N 
 
M 
 
GRP 
 
Basal 
PSA 
 
5092/93B 
 
2 
 
3 
 
1 
 
2 
 
3 
 
19 
 
53 
 
56 
 
33 
 
0 
 
0 
 
8 
 
13 
 
2101/94 #4 
 
2 
 
1 
 
2 
 
2 
  
1 
 
50 
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DISCUSSION 
 
The natural history of prostate carcinomas remains elusive thus far, whether on 
how they evolve, disseminate and how they can be treated based on their 
unique features. Therefore, numerous efforts have been made and research 
has been particularly focused on identifying novel molecular markers or 
alterations that underline the ignition and progression of prostate neoplasms 
and can hopefully improve the accuracy of both diagnosis and therapeutic 
approaches.  
In recent years, the notion that a small group of stem cells intervenes in the 
process of neoplastic transformation lead to the emergence of a novel theory 
regarding cancer. Indeed, cancer stem cells (CSCs) or tumor initiating cells 
(TICs) are believed to have the ability to generate an entire tumor. Among their 
features is the unlimited capacity of proliferation, self-renewal and also the 
extraordinary resistance to either chemotherapeutic or radiotherapy regimens 
(Reya et al., 2001). Hence, this small subset of cells persevering in the tumor 
microenvironment has been acknowledged to be a dominant determinant in the 
processes of development, progression, metastasis and recurrence of a tumor 
(Akunuro et al., 2011). In this regard, a group of stem cell reprograming factors 
is emerging as oncogenes in a myriad of cancers (Jeter et al., 2009; Karoubi et 
al., 2009). Among these, is the human transcription factor SOX2. This gene 
participates in cellular fate determination, differentiation and also proliferation 
processes (Takahashi et al., 2007; Chew et al., 2009). It is highly expressed in 
embryonic stem cells (Fong et al., 2008). More recently, SOX2 has been linked 
to the anomalous growth of numerous types of human solid tumors and to a 
promising contribution to CSCs (Gu et al., 2007; Kasper, 2008).  In fact, 
expression of SOX2 has been shown in melanoma (Laga et al., 2011), digestive 
tract (Otsubo et al., 2008; Saigusa et al., 2009), breast (Chen et al., 2008), liver 
(Huang et al., 2011), pancreatic (Sanada et al., 2006) and lung carcinoma 
(Hussenet and Manoir, 2010). In prostate settings, SOX2 was previously 
established to be an AR repressed gene (Kregel et al., 2013). Its expression 
closely associates to the progression and aggressiveness of PC (Jia et al., 
2011; Liu et al., 2013; Weina and Utikal, 2014; Russo et al., 2015). 
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Nevertheless, the dynamics and regulation of its activities and, most 
importantly, the ultimate clinical pathological impact lingers to be unveiled. As 
such, significant insights into the mechanist underlining the expression and role 
employed by SOX2 will provide a major step forward towards understanding the 
biological processes prevailing in the development and progression of prostate 
carcinomas. 
In the present work we used a series of PC cell lines and patient samples to 
assess the effect of SOX2 on the biological behaviour of PC cells. To elucidate 
the role of SOX2 in prostate carcinomas, we started by screening a panel of 
prostate tumor cell lines for SOX2 by Western blot and immunohistochemistry 
analysis. We showed that the androgen independent and highly metastatic PC3 
cell line expressed the protein. These findings further suggest that SOX2 
possibly contributes to the tumorigenicity of PC. Moreover, immunofluorescence 
analysis revealed that SOX2 is located mostly in the nucleus of PC3 cells 
though a slight cytoplasmic staining was also observed. The mechanism 
involved in SOX2 cellular location regulation is poorly understood. While its 
nuclear localization points to a possible engagement in the transcriptional 
activity regulation of several genes, SOX2 ultimate function in the cytosol is 
unknown. Our results are in agreement with a previous study who also report a 
dual location, but mostly nuclear, for SOX2 in the PC3 cell line by 
immunofluorescence analysis (Jia et al., 2011). 
To assess the effect of SOX2 inhibition by siRNA-mediated knock-down in the 
biological behaviour of PC cell lines, we proceeded to several in vitro studies. 
We performed a cell morphology assay during 3 days and it was observed that 
SOX2 knock-down did not affect cell morphology. At day 3, PC3 cells 
transfected with siSOX2 showed the same phenotype when compared with 
scrambled control cells. Thus, it is feasible to contemplate the trivial impact of 
SOX2 in what regards the morphological features of PC cells. Prior studies 
dedicated to SOX2 expression in PC cell lines did not explore morphologic 
features in detail. Nonetheless, in a study performed by Lundberg and 
colleagues (2016) the human colon cancer cell line Caco2 expressing high 
levels of SOX2 displayed a less adherent and spheroid growth pattern when 
compared to the wild type counterparts (Lundberg et al., 2016). Moreover, lung 
squamous cell carcinomas expressing SOX2 were found to display a higher 
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grade of nuclear atypia, with larger and often abnormal nuclei with or without 
nucleoli (Brcic et al., 2012). SOX2 elevation was also found to promote 
physiological changes to more differentiated phenotypes in the medullobastoma 
DAOY cell line (Cox et al., 2012). 
We also evaluated cell death in both PNT2 and PC3 cell lines. As expected for 
the PNT2 cell line, the percentage of apoptotic cells was not significantly 
affected by SOX2 knock-down when compared to the control conditions. 
Nevertheless, we observed a significant increase in the number of PC3 siSOX2 
transfected cells undergoing apoptosis. Hence, SOX2 appears to be a pivotal 
intervenient for human PC cells survival processes. The role of SOX2 in 
programmed cancer cell death was addressed by some studies. Jia and 
collaborators (2011) found that SOX2 is capable of improving the anti-apoptotic 
and chemotherapeutic resistance features of PC cells (Jia et al., 2011). Similar 
deductions were accomplished in distinct tumor models. In ovarian cancer 
settings, the apoptotic resistance capacities of cancer cells were boosted after 
SOX2 overexpression (Bareiss et al., 2013). In addition, SOX2 knock-down in 
human gastric cancer cell lines led to a significant stimulation of the apoptotic 
process (Otsubo et al., 2011). Research thus far leads to the consensus that 
SOX2 primarily acts as an anti-apoptotic factor in several types of human solid 
cancers. Furthermore, and despite some uncertainty, SOX2 activities have 
been documented to be cancer specific, i.e., SOX2 regulates distinct sets of 
apoptotic genes depending upon the organ affected. For instance, in PC 
backgrounds SOX2 overexpression diminished the store-operated calcium entry 
(SOCE) activity that further enhanced the anti-apoptotic properties of SOX2 (Jia 
et al., 2011). Furthermore, SOX2 silencing was found to induce apoptosis by 
up-regulating p27, down-regulating cyclin E and suppressing the expression of 
survinin (Lin et al., 2012). Conversely, in lung cancer settings, Chou and 
colleagues (2013) reported that SOX2 knock-down stimulated apoptosis and 
autophagy through BCL2L1 down-regulation (Chou et al., 2013). In summary, 
the concept that CSCs possess higher-resistance properties when compared to 
more differentiated cancer cells (Mimeault and Batra, 2006; Mimeault and 
Batra, 2007; Baumman et al., 2008) is on the basis cancer recurrence. A better 
understanding into this subject may lead to the development of novel effective 
approaches capable of inducing cancer stem cells death and thus avoid cancer 
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relapse. To this end, targeting the presumable anti-apoptotic SOX2 gene is 
emerging as a promising strategy for cancer therapy; however the processes 
and pathways where it operates and ultimately promotes the survival of PC cells 
requires further investigation. 
The clinical course of PC is variable and difficult to predict. While some tumors 
remain organ-confined, others might metastasize even in early stages of the 
disease. The metastatic process comprises the main cause of cancer 
associated mortality (Chambers et al., 2002). Through specific migratory and 
invasive processes human PC cells preferentially metastasize to the bone 
(Harada et al., 1992; Bubendorf et al., 2004). Indeed, the conception of bony 
PC colonies encompasses an intricate and coordinated process involving i) 
displacement from a primary site; (ii) resistance to anoikis during circulation; (iii) 
binding to bone marrow cells and (iv) survival and growth in the bone 
microenvironment (Ibrahim et al., 2010). However, the molecular mechanisms 
underlying the establishment of these niches are still poorly understood but of 
pressing need due to the overwhelming mortality to them associated. The initial 
stages of metastasis are largely reliant on an eclectic range of mobility and 
invasive machineries (Friedl and Wolf, 2003). Indeed, primary tumor mass cells 
commitment to malignancy requires loss of differentiated features and 
consequential gain of mesenchymal properties, including increased motility and 
invasiveness (Kalluri and Weinberg, 2009). This process has been known as 
epithelial to mesenchymal transition (EMT) (Micalizzi et al., 2010).  As in other 
types of cancer (Weina and Utikal, 2014), in prostate carcinomas SOX2 is 
closely associated with invasion largely through protein overexpression (Jia et 
al., 2011; Kregel et al., 2013). Taking these findings into consideration, we 
decided to perform in vitro wound-healing assays to determine whether or not 
SOX2 knock-down would also affect the migratory capacity of PC cells. Results 
obtained by time-lapse acquisition allowed the observation of cell migration in 
both PNT2 and PC3 cell lines during a wound healing of 18 hours. Cell 
migration was evaluated. Regarding the PNT2 cell line, not surprisingly, siSOX2 
transfected cells migrated in a similar manner as scrambled controls in order to 
close the wound. However, in the PC3 cell line, it was clearly observed that 
siSOX2 transfected cells migrated to close the wound in a minor extent and 
moved slower, when compared to scrambled transfected cells. These 
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observations suggest that the knock-down of SOX2 expression promoted a 
significant decrease in cell migration rates, resulting in an impaired ability to 
close the wound. To our knowledge there is no report addressing the migration 
capability of PC cell lines after SOX2 inhibition by wound healing. Nevertheless, 
our results are in agreement with a recent paper published by Russo and 
collaborators (2015) wherein SOX2 overexpression in PC3 and 22RV1 cell lines 
significantly enlarged their invasive and migratory abilities when compared to 
empty vector transfected cells (Russo et al., 2015). Several studies support the 
probable contribution of SOX2 in the proliferation, migration, invasion and 
metastatic processes in various cellular models including glioblastomas (Alonso 
et al., 2011), colorectal cancer (Han et al., 2012; Li et al., 2013), breast cancer 
(Leis et al., 2012), lung cancer (Hussenet et al., 2010) and osteosarcomas 
(Basu-Roy et al., 2012). Indeed, the expression profile of SOX2 in human solid 
tumors has been positively correlated with their invasiveness and metastatic 
potential. To our knowledge, the orchestration of complex biological responses, 
such as cell motility, by SOX2 is largely unknown. The opening rounds of 
metastasis embroil loss of adhesion between tumor cells and subsequent 
shedding and invasion to other locations. Metalloproteinases (MMPs), namely 
MMP-2 and MMP-9, role in this process is paramount; by promoting the 
degradation of the ECM and decreasing cellular adhesion they stimulate the 
migration of cells during metastasis (Mook et al., 2004). Some studies had 
focused on the actual role of SOX2 in human cancer cell motility. SOX2 
overexpression significantly increased the number of cells undergoing migratory 
and invasive processes in the SOX2-negative glioma cell line U-87 (Alonso et 
al., 2011). Furthermore, in colorectal cancer cells, SOX2 was found to be 
involved in the migration and invasion process via MMP-2 (Han et al., 2012). 
Similarly, SOX2 was able to induce migration and invasion via MMP2 and the 
PI3K/AKT/mTOR pathway in laryngeal squamous cell carcinoma (LSCC) (Yang 
et al., 2014). SOX2 overexpression was found to promote migration and 
invasion of ovarian cancer cells by directly regulating fibronectin 1 (FN1), a 
protein involved in cell motility processes, which in turn induces the expression 
of both MMP2 and MMP9 (Lou et al., 2013). FN1 was also found to induce the 
expression of MMP2 in human PC cells (Moroz et al., 2012) but to our 
knowledge there is no study aimed at assessing the role employed by SOX2 in 
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the regulation of MMPs in progression of prostate carcinomas. In summary, our 
results are in agreement with several studies supporting a SOX2 pivotal role in 
promoting mobility capacities of cancer cells.  Nevertheless, the molecular 
mechanisms underlining this activity on PC requires further elucidation. 
The participation of SOX2 in distinct facets of cancer biology is more than 
proven. Nevertheless, the clinical importance of this transcription factor in terms 
of prognosis, recurrence and resistance to therapy is also supreme for a better 
understanding of the disease. A host of human solid tumors have been 
acknowledged to express SOX2 thought its role and concomitant clinical value 
is notoriously debatable. Nevertheless, the expression of SOX2 has been 
positively associated to tumor grade and poorer prognosis in the majority of 
human cancers types, including hepatocellular carcinoma (Sun et al., 2013), 
colorectal cancer (Neumann et al., 2011), lung cancer (Yung et al., 2013), 
gastric cancer (Zhang et al., 2010) and LSCC (Tang et al., 2013).   
To assess if SOX2 plays an important role in the development of prostate 
neoplams we proceeded to immunohistochemistry analysis of human PC tissue 
in a small series of ten patients. We found that expression of SOX2 was higher 
in cancerous in comparison to normal adjacent tissues. These findings were 
consistence to those of various publications (Jia et al., 2011; Bourguignon et al., 
2012; Schorck et al., 2013; Ye et al., 2013) where an increase in the expression 
of SOX2 is perceived in the tumor, but not in normal-adjacent tissue. In PC 
settings, protein expression of SOX2 has been described to be both increased 
(Jia et al., 2011; Ugolkov et al., 2011) and decreased (Yu et al., 2014; Russo et 
al., 2015) in organ-confined tumors, when compared to their normal 
counterparts. Nevertheless, based on our results, we believe that SOX2 
increased expression may be related to the tumorigenesis of the prostate. As 
such, we decided to evaluate the actual link between SOX2 expression and the 
tumorigenic process. We performed a statistical analysis to ascertain the 
possible relationship of SOX2 with a series of clinical and histopathological 
guidelines. Concerning pathological grade, the T tumor size, and stage we did 
not find any association to SOX2 expression. Both SOX2-positive and negative 
tumors displayed similar grade, size and stage. We believe that the discrepancy 
observed in our results might be accredited to the small cohort of samples 
analysed. These results do not corroborate the available literature. Indeed, the 
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expression of SOX2 in PC tissue was previously related to tumor grade, i.e., the 
percentage of SOX2-positive cells increases with Gleason score (Jia et al., 
2011; Kregel et al., 2013). Similar results were obtained in breast cancer 
models wherein the expression of SOX2 had positively correlated with the TNM 
stage and histological grade (Stolzenburg et al., 2012). Furthermore, in 
esophageal cancer SOX2 co-localization with OCT3/4 was found to be closely 
associated with higher stage (Wang et al., 2009). In ovarian cancer settings, 
SOX2 overexpression has been related to poorer clinical prognosis (Ye et al., 
2011; Zhang et al., 2012), i.e., lymphatic and vascular invasion, poorly 
differentiated neoplasms and incomplete resection (Lou et al., 2012). SOX2 
expression was also associated with clinical stage in patients diagnosed with 
small cell lung cancer (Yang et al., 2013) and LSCC (Tang et al., 2013).  
Concerning the regional status of lymph nodes we surprisingly found that 
patients bearing SOX2-negative tumors were closely associated to the 
presence of metastasis in the lymph nodes. It seems that SOX2-negative 
tumors are more prone to develop regional metastasis to the lymph nodes than 
those of SOX2-positive tumors. These results are in disagreement with the 
majority of data available on the literature. For instance, SOX2 overexpression 
was previously found to be closely associated to the presence of metastasis in 
the lymph nodes in PC (Russo et al., 2015), small cell lung cancer (Yang et al., 
2013) and gastric cancer (Matsuoka et al., 2012). 
Regarding the relationship of SOX2 with tumor recurrence, we found that 
patients bearing SOX2-positive tumors were significantly associated with an 
increased D’Amico risk. Although a potential correlation between SOX2, 
disease-free, and disease survival was also observed, i.e., patients bearing 
SOX2-positive tumors revealed shorter disease-free survival duration, the 
results did not reach statistical significance and thus not consent the 
establishment of a definitive conclusion. Nevertheless, these data imply a 
probable SOX2 involvement in tumor recurrence and are in accordance in some 
previous studies. Russo and colleagues (2015) suggest a correlation between 
SOX2 expression in PC and biochemical recurrence-free survival (Russo et al., 
2015).  In ovarian cancer settings, SOX2 overexpression has been related to 
shorter disease-free survival durations (Zhang et al., 2012). Similar outcomes 
were obtained in hepatocellular carcinoma and esophageal squamous cancer 
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models, where SOX2 was able to convene larger disease aggressiveness, as 
males harboring SOX2-positive neoplams revealed significant shorter survival 
periods (Wang et al., 2009; Huang et al., 2011). Moreover, in sinonasal cancer 
SOX2 amplification was established to identify cancers which are more likely to 
relapse (Schröck et al., 2013). In contrast, Otsubo and colleagues (2008) 
reported that the expression of SOX2 is frequently downregulated in human 
gastric cancer and confers shorter survival periods and tumor suppressor 
features in gastric carcinogenesis (Otsubo et al., 2008). 
In conclusion, we have consolidated SOX2 as a pivotal player in the 
progression of prostatic neoplams. Upon SOX2 knock-down mediated by 
siRNAs a decrease in the migratory capacities, as well as an increase in the 
number of cells undergoing apoptosis, was perceived. These results further 
support the premise that SOX2 may take part of an important transcriptional 
program responsible for ultimately driving malignancy. We also found that the 
protein expression of SOX2 in cancerous tissues is increased in comparison to 
the normal adjacent tissue. In addition, SOX2 closely associates with some 
clinical and pathological criteria, including risk of relapsing after therapy, further 
pointing to a potential participation in tumor recurrence mechanisms. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
SOX2 a master gene regulating prostate cancer progression?  
 
 72 
CONCLUSION 
 
 
 
The present study showed that SOX2 plays an important role in the biological 
behavior of PC cell lines. SOX2 silencing mediated by siRNAs demonstrated 
that it acts during PC progression since we found a decrease in the migration 
capacity and also an increase in apoptosis of SOX2 knocked-down PC3 cells. 
SOX2 plays an important role in the biological behavior and subpopulation 
pattern of PC since it also affected the apoptosis resistance of PC3 cells, which 
showed increased expression of solely Annexin V or PI and Annexin V with 
concomitant early and late apoptosis, respectively. 
Moreover, in what regards SOX2 expression pattern, basal-like cells 
overexpressed the protein in patient PC samples and significant associations 
with some important clinical criteria, including the risk of relapsing after therapy. 
These observations point to an important role of SOX2 in PC. Expression and 
activity of SOX2 is possibly involved in early tumor progression, invasion and 
relapse after therapy. These results indicate that the discovery of a SOX2 
repressor could potentially be used for anti-cancer therapy.  
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